Home » Stocks » BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. (BCRX)

Stock Price: $3.96 USD 0.00 (0.00%)
Updated Aug 12, 2020 11:10 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 698.55M
Revenue (ttm) 49.19M
Net Income (ttm) -116.42M
Shares Out 176.43M
EPS (ttm) -0.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $3.96
Previous Close $3.96
Change ($) 0.00
Change (%) 0.00%
Day's Open 3.99
Day's Range 3.93 - 4.07
Day's Volume 1,606,662
52-Week Range 1.38 - 6.29

More Stats

Market Cap 698.55M
Enterprise Value 592.44M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 176.43M
Float 154.93M
EPS (basic) -0.8
EPS (diluted) -0.84
FCF / Share -0.57
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 32.10M
Short Ratio 3.64
Short % of Float 18.95%
Beta 2.75
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 14.20
PB Ratio 192.00
Revenue 49.19M
Operating Income -114.70M
Net Income -116.42M
Free Cash Flow -92.76M
Net Cash 106.11M
Net Cash / Share 0.60
Gross Margin -126.71%
Operating Margin -233.15%
Profit Margin -236.70%
FCF Margin -188.55%
ROA -49.79%
ROE -882.75%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 6
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.50*
(114.65% upside)
Low
4.50
Current: $3.96
High
13.00
Target: 8.50
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue48.8420.6525.1926.3548.2613.6117.3326.2919.6462.38
Revenue Growth136.45%-18%-4.43%-45.39%254.62%-21.48%-34.09%33.85%-68.51%-
Gross Profit44.7320.1823.4823.6546.3613.4917.2326.1619.6462.30
Operating Income-99.46-94.22-57.41-48.61-39.44-45.77-30.72-33.89-49.59-34.36
Net Income-109-101-65.78-55.14-43.02-45.19-30.11-39.08-56.95-33.85
Shares Outstanding11610384.4573.7072.9066.7755.2249.4745.1444.56
Earnings Per Share-0.94-0.98-0.78-0.75-0.59-0.68-0.55-0.79-1.26-0.76
Operating Cash Flow-89.58-92.57-41.14-53.44-13.12-38.55-26.53-37.40-32.25-28.56
Capital Expenditures-0.34-0.37-0.32-5.27-5.12-0.110.02-0.11-0.06-0.33
Free Cash Flow-89.93-92.93-41.46-58.71-18.24-38.66-26.51-37.51-32.31-28.88
Cash & Equivalents13810611856.2053.1872.9238.2135.9142.3454.57
Total Debt84.6561.8254.7253.7230.1830.0030.0030.0030.00-
Net Cash / Debt53.1244.1962.962.4723.0042.928.215.9112.3454.57
Assets17514717889.8512213748.8757.4482.21109
Liabilities13797.6194.4988.2774.6461.2449.9957.8967.4043.94
Book Value38.2549.2483.771.5847.7275.64-1.13-0.4514.8165.50
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name BioCryst Pharmaceuticals, Inc.
Country United States
Employees 140
CEO Jon P. Stonehouse

Stock Information

Ticker Symbol BCRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BCRX
IPO Date March 3, 1994

Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.